Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07, 2024 08:00 ET
|
Biora Therapeutics, Inc.
The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
May 06, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
April 30, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
April 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024 08:00 ET
|
Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 03, 2024 16:05 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 01, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 16:05 ET
|
Biora Therapeutics, Inc.
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt